Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,629 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study.
Pan Y, Zhu X, Liu J, Zhong J, Zhang W, Shen S, Jin R, Liu H, Ye F, Hu K, Xu D, Zhang Y, Chen Z, Xing B, Zhou L, Chen Y, Zeng Y, Liang X, Kuang M, Song T, Xiang B, Wang K, Sun H, Xu L; China Liver Cancer Study Group Young Investigators (CLEAP). Pan Y, et al. Among authors: ye f. Front Immunol. 2023 Apr 26;14:1138355. doi: 10.3389/fimmu.2023.1138355. eCollection 2023. Front Immunol. 2023. PMID: 37180173 Free PMC article.
Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study.
Zhang X, Zhu X, Zhong J, Zhao Y, Zhang X, Zhang W, Ye F, Yang C, Xue J, Xiong R, Wang J, Shen S, Pan Y, Li D, Song T, Bi X, Sun H, Xiang B, Gu S, Wen T, Lu S, Chen Y, Yin T, Liu L, Kuang M, Xu L, Li D, Cai J. Zhang X, et al. Among authors: ye f. Sci Rep. 2024 Apr 28;14(1):9745. doi: 10.1038/s41598-024-60379-x. Sci Rep. 2024. PMID: 38679630 Free PMC article.
The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
Yang CX, Pan YX, Ye F, Zhu XD, Xue J, Li X, Yuan ZG, Zhang L, Xu L, Chen YJ, Wang NY, Sun HC, Liu XF; China Liver Cancer Study Group Young Investigators (CLEAP). Yang CX, et al. Among authors: ye f. Front Immunol. 2024 Apr 22;15:1310239. doi: 10.3389/fimmu.2024.1310239. eCollection 2024. Front Immunol. 2024. PMID: 38711515 Free PMC article.
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
Zhang P, Chen Z, Shi S, Li Z, Ye F, Song L, Zhang Y, Yin F, Zhang X, Xu J, Cheng Y, Su W, Shi M, Fan S, Tan P, Zhong C, Lu M, Shen L. Zhang P, et al. Among authors: ye f. Cancer Immunol Immunother. 2024 May 7;73(7):119. doi: 10.1007/s00262-024-03677-7. Cancer Immunol Immunother. 2024. PMID: 38713205 Free PMC article. Clinical Trial.
4,629 results